Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

How reliable is dietary supplement labelling?-Experiences from the analysis of ecdysterone supplements.

Ambrosio G, Wirth D, Joseph JF, Mazzarino M, de la Torre X, Botrè F, Parr MK.

J Pharm Biomed Anal. 2020 Jan 5;177:112877. doi: 10.1016/j.jpba.2019.112877. Epub 2019 Sep 11.

PMID:
31568967
2.

Fine-mapping of the substrate specificity of human steroid 21-hydroxylase (CYP21A2).

Stoll A, Loke S, Joseph JF, Machalz D, de la Torre X, Botrè F, Wolber G, Bureik M, Parr MK.

J Steroid Biochem Mol Biol. 2019 Nov;194:105446. doi: 10.1016/j.jsbmb.2019.105446. Epub 2019 Aug 9.

PMID:
31404637
3.

Forced Degradation Testing as Complementary Tool for Biosimilarity Assessment.

Dyck YFK, Rehm D, Joseph JF, Winkler K, Sandig V, Jabs W, Parr MK.

Bioengineering (Basel). 2019 Jul 21;6(3). pii: E62. doi: 10.3390/bioengineering6030062.

4.

Ecdysteroids as non-conventional anabolic agent: performance enhancement by ecdysterone supplementation in humans.

Isenmann E, Ambrosio G, Joseph JF, Mazzarino M, de la Torre X, Zimmer P, Kazlauskas R, Goebel C, Botrè F, Diel P, Parr MK.

Arch Toxicol. 2019 Jul;93(7):1807-1816. doi: 10.1007/s00204-019-02490-x. Epub 2019 May 23.

PMID:
31123801
5.

Metabolism of formestane in humans: Identification of urinary biomarkers for antidoping analysis.

de la Torre X, Martinez Brito D, Colamonici C, Parr MK, Botrè F.

Steroids. 2019 Jun;146:34-42. doi: 10.1016/j.steroids.2019.03.005. Epub 2019 Mar 20.

PMID:
30904502
6.

Conversion of chenodeoxycholic acid to cholic acid by human CYP8B1.

Fan L, Joseph JF, Durairaj P, Parr MK, Bureik M.

Biol Chem. 2019 Apr 24;400(5):625-628. doi: 10.1515/hsz-2018-0379.

PMID:
30465713
7.

NDMA impurity in valsartan and other pharmaceutical products: Analytical methods for the determination of N-nitrosamines.

Parr MK, Joseph JF.

J Pharm Biomed Anal. 2019 Feb 5;164:536-549. doi: 10.1016/j.jpba.2018.11.010. Epub 2018 Nov 12. Review.

PMID:
30458387
8.

Toxicological findings in suicides - frequency of antidepressant and antipsychotic substances.

Methling M, Krumbiegel F, Hartwig S, Parr MK, Tsokos M.

Forensic Sci Med Pathol. 2019 Mar;15(1):23-30. doi: 10.1007/s12024-018-0041-4. Epub 2018 Nov 5.

PMID:
30397872
9.
10.

Structure assisted impurity profiling for rapid method development in liquid chromatography.

Schmidtsdorff S, Schmidt AH, Parr MK.

J Chromatogr A. 2018 Nov 23;1577:38-46. doi: 10.1016/j.chroma.2018.09.044. Epub 2018 Sep 24.

PMID:
30274690
11.

SFC for chiral separations in bioanalysis.

Harps LC, Joseph JF, Parr MK.

J Pharm Biomed Anal. 2019 Jan 5;162:47-59. doi: 10.1016/j.jpba.2018.08.061. Epub 2018 Sep 3. Review.

PMID:
30223142
12.

Splitless hyphenation of SFC with MS by APCI, APPI, and ESI exemplified by steroids as model compounds.

Parr MK, Wüst B, Teubel J, Joseph JF.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Aug 1;1091:67-78. doi: 10.1016/j.jchromb.2018.05.017. Epub 2018 May 16.

PMID:
29852383
13.

Drug-drug interaction and doping: Effect of non-prohibited drugs on the urinary excretion profile of methandienone.

Mazzarino M, Khevenhüller-Metsch FL, Fiacco I, Parr MK, de la Torre X, Botrè F.

Drug Test Anal. 2018 Oct;10(10):1554-1565. doi: 10.1002/dta.2406. Epub 2018 Jul 1.

PMID:
29766657
14.

Androgen- and estrogen-receptor mediated activities of 4-hydroxytestosterone, 4-hydroxyandrostenedione and their human metabolites in yeast based assays.

Keiler AM, Zierau O, Wolf S, Diel P, Schänzer W, Vollmer G, Machalz D, Wolber G, Parr MK.

Toxicol Lett. 2018 Aug;292:39-45. doi: 10.1016/j.toxlet.2018.04.026. Epub 2018 Apr 24.

PMID:
29702199
15.

Methods in endogenous steroid profiling - A comparison of gas chromatography mass spectrometry (GC-MS) with supercritical fluid chromatography tandem mass spectrometry (SFC-MS/MS).

Teubel J, Wüst B, Schipke CG, Peters O, Parr MK.

J Chromatogr A. 2018 Jun 15;1554:101-116. doi: 10.1016/j.chroma.2018.04.035. Epub 2018 Apr 17.

PMID:
29699872
16.

Combined chemical and biotechnological production of 20βOH-NorDHCMT, a long-term metabolite of Oral-Turinabol (DHCMT).

Liu J, Chen L, Joseph JF, Naß A, Stoll A, de la Torre X, Botrè F, Wolber G, Parr MK, Bureik M.

J Inorg Biochem. 2018 Jun;183:165-171. doi: 10.1016/j.jinorgbio.2018.02.020. Epub 2018 Feb 26.

PMID:
29544993
17.

Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept.

Montacir O, Montacir H, Springer A, Hinderlich S, Mahboudi F, Saadati A, Parr MK.

Protein J. 2018 Apr;37(2):164-179. doi: 10.1007/s10930-018-9757-y.

PMID:
29411222
18.

Bioengineering of rFVIIa Biopharmaceutical and Structure Characterization for Biosimilarity Assessment.

Montacir O, Montacir H, Eravci M, Springer A, Hinderlich S, Mahboudi F, Saadati A, Parr MK.

Bioengineering (Basel). 2018 Jan 19;5(1). pii: E7. doi: 10.3390/bioengineering5010007.

19.

Effect of non-prohibited drugs on the phase II metabolic profile of morphine. An in vitro investigation for doping control purposes.

Ambrosio G, de la Torre X, Mazzarino M, Parr MK, Botrè F.

Drug Test Anal. 2018 Jun;10(6):984-994. doi: 10.1002/dta.2344. Epub 2018 Jan 25.

PMID:
29172026
20.

Photostability testing using online reactor HPLC hyphenation and mass spectrometric compound identification illustrated by ketoprofen as model compound.

Assaf J, Gomes DZ, Wuest B, Parr MK.

J Pharm Biomed Anal. 2017 Oct 25;145:414-422. doi: 10.1016/j.jpba.2017.07.006. Epub 2017 Jul 8.

PMID:
28732306
21.

Polyglycerol-opioid conjugate produces analgesia devoid of side effects.

González-Rodríguez S, Quadir MA, Gupta S, Walker KA, Zhang X, Spahn V, Labuz D, Rodriguez-Gaztelumendi A, Schmelz M, Joseph J, Parr MK, Machelska H, Haag R, Stein C.

Elife. 2017 Jul 4;6. pii: e27081. doi: 10.7554/eLife.27081.

22.

Life cycle management of analytical methods.

Parr MK, Schmidt AH.

J Pharm Biomed Anal. 2018 Jan 5;147:506-517. doi: 10.1016/j.jpba.2017.06.020. Epub 2017 Jun 17. Review.

PMID:
28666555
23.

Comparability study of Rituximab originator and follow-on biopharmaceutical.

Montacir O, Montacir H, Eravci M, Springer A, Hinderlich S, Saadati A, Parr MK.

J Pharm Biomed Anal. 2017 Jun 5;140:239-251. doi: 10.1016/j.jpba.2017.03.029. Epub 2017 Mar 19.

PMID:
28371718
24.

[Nutritional supplements in sports - sense, nonsense or hazard?]

Parr MK, Schmidtsdorff S, Kollmeier AS.

Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017 Mar;60(3):314-322. doi: 10.1007/s00103-016-2498-1. Review. German.

PMID:
28058459
25.

Distinction of clenbuterol intake from drug or contaminated food of animal origin in a controlled administration trial - the potential of enantiomeric separation for doping control analysis.

Parr MK, Blokland MH, Liebetrau F, Schmidt AH, Meijer T, Stanic M, Kwiatkowska D, Waraksa E, Sterk SS.

Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2017 Apr;34(4):525-535. doi: 10.1080/19440049.2016.1242169. Epub 2016 Oct 26.

PMID:
27690842
26.

SFC-MS/MS as an orthogonal technique for improved screening of polar analytes in anti-doping control.

Parr MK, Wuest B, Naegele E, Joseph JF, Wenzel M, Schmidt AH, Stanic M, de la Torre X, Botrè F.

Anal Bioanal Chem. 2016 Sep;408(24):6789-97. doi: 10.1007/s00216-016-9805-4. Epub 2016 Aug 23.

PMID:
27553949
27.
28.

Physicochemical characterization of biopharmaceuticals.

Parr MK, Montacir O, Montacir H.

J Pharm Biomed Anal. 2016 Oct 25;130:366-389. doi: 10.1016/j.jpba.2016.05.028. Epub 2016 May 18. Review.

PMID:
27324698
29.

Synthetic androgens as designer supplements.

Joseph JF, Parr MK.

Curr Neuropharmacol. 2015 Jan;13(1):89-100. doi: 10.2174/1570159X13666141210224756. Review.

30.

Ecdysteroids: A novel class of anabolic agents?

Parr MK, Botrè F, Naß A, Hengevoss J, Diel P, Wolber G.

Biol Sport. 2015 Jun;32(2):169-73. doi: 10.5604/20831862.1144420. Epub 2015 Mar 15.

31.

Combined effects of androgen anabolic steroids and physical activity on the hypothalamic-pituitary-gonadal axis.

Hengevoss J, Piechotta M, Müller D, Hanft F, Parr MK, Schänzer W, Diel P.

J Steroid Biochem Mol Biol. 2015 Jun;150:86-96. doi: 10.1016/j.jsbmb.2015.03.003. Epub 2015 Mar 19.

PMID:
25797375
32.

What is the potential of measuring the enantiomeric ratio of drugs using supercritical fluid chromatography-MS?

Parr MK, Schmidt AH.

Bioanalysis. 2014;6(24):3267-70. doi: 10.4155/bio.14.255. No abstract available.

PMID:
25534784
33.

Detection of formestane abuse by mass spectrometric techniques.

de la Torre X, Colamonici C, Curcio D, Jardines D, Molaioni F, Parr MK, Botrè F.

Drug Test Anal. 2014 Nov-Dec;6(11-12):1133-40. doi: 10.1002/dta.1759.

PMID:
25516450
34.

The influence of chronic L-carnitine supplementation on the formation of preneoplastic and atherosclerotic lesions in the colon and aorta of male F344 rats.

Empl MT, Kammeyer P, Ulrich R, Joseph JF, Parr MK, Willenberg I, Schebb NH, Baumgärtner W, Röhrdanz E, Steffen C, Steinberg P.

Arch Toxicol. 2015 Nov;89(11):2079-87. doi: 10.1007/s00204-014-1341-4. Epub 2014 Aug 28.

PMID:
25164827
35.

Estrogen receptor beta is involved in skeletal muscle hypertrophy induced by the phytoecdysteroid ecdysterone.

Parr MK, Zhao P, Haupt O, Ngueu ST, Hengevoss J, Fritzemeier KH, Piechotta M, Schlörer N, Muhn P, Zheng WY, Xie MY, Diel P.

Mol Nutr Food Res. 2014 Sep;58(9):1861-72. doi: 10.1002/mnfr.201300806. Epub 2014 Jun 27.

PMID:
24974955
36.

Unexpected contribution of cytochrome P450 enzymes CYP11B2 and CYP21, as well as CYP3A4 in xenobiotic androgen elimination - insights from metandienone metabolism.

Parr MK, Zöllner A, Fusshöller G, Opfermann G, Schlörer N, Zorio M, Bureik M, Schänzer W.

Toxicol Lett. 2012 Sep 18;213(3):381-91. doi: 10.1016/j.toxlet.2012.07.020. Epub 2012 Jul 31.

PMID:
22885098
37.

Characterization of identity, metabolism and androgenic activity of 17-hydroxyandrosta-3,5-diene by GC-MS and a yeast transactivation system.

Bauer A, Rataj F, Zierau O, Anielski P, Große J, Parr MK, Vollmer G, Thieme D.

Arch Toxicol. 2012 Dec;86(12):1873-84. doi: 10.1007/s00204-012-0905-4. Epub 2012 Jul 19.

PMID:
22811023
38.

Endocrine characterization of the designer steroid methyl-1-testosterone: investigations on tissue-specific anabolic-androgenic potency, side effects, and metabolism.

Parr MK, Blatt C, Zierau O, Hess C, Gütschow M, Fusshöller G, Opfermann G, Schänzer W, Diel P.

Endocrinology. 2011 Dec;152(12):4718-28. doi: 10.1210/en.2011-1164. Epub 2011 Oct 11.

PMID:
21990312
39.

Seized designer supplement named "1-Androsterone": identification as 3β-hydroxy-5α-androst-1-en-17-one and its urinary elimination.

Parr MK, Opfermann G, Geyer H, Westphal F, Sönnichsen FD, Zapp J, Kwiatkowska D, Schänzer W.

Steroids. 2011 May;76(6):540-7. doi: 10.1016/j.steroids.2011.02.001. Epub 2011 Feb 16.

PMID:
21310167
40.

Detection of Δ6-methyltestosterone in a "dietary supplement" and GC-MS/MS investigations on its urinary metabolism.

Parr MK, Fusshöller G, Schlörer N, Opfermann G, Geyer H, Rodchenkov G, Schänzer W.

Toxicol Lett. 2011 Mar 5;201(2):101-4. doi: 10.1016/j.toxlet.2010.11.018. Epub 2010 Dec 4.

PMID:
21134425
41.

A novel combined approach to detect androgenic activities with yeast based assays in Schizosaccharomyces pombe and Saccharomyces cerevisiae.

Wolf S, Rataj F, Zierau O, Ostermann K, Diel P, Parr MK, Vollmer G, Rödel G.

Toxicol Lett. 2010 Dec 15;199(3):410-5. doi: 10.1016/j.toxlet.2010.10.007. Epub 2010 Oct 12.

PMID:
20946944
42.

Long-term detection of methyltestosterone (ab-) use by a yeast transactivation system.

Wolf S, Diel P, Parr MK, Rataj F, Schänzer W, Vollmer G, Zierau O.

Arch Toxicol. 2011 Apr;85(4):285-92. doi: 10.1007/s00204-010-0590-0. Epub 2010 Oct 6.

PMID:
20924560
43.

Investigations of the microbial transformation of cortisol to prednisolone in urine samples.

Bredehöft M, Baginski R, Parr MK, Thevis M, Schänzer W.

J Steroid Biochem Mol Biol. 2012 Mar;129(1-2):54-60. doi: 10.1016/j.jsbmb.2010.04.021. Epub 2010 Apr 29.

PMID:
20435141
44.

Development of criteria for the detection of adrenosterone administration by gas chromatography-mass spectrometry and gas chromatography-combustion-isotope ratio mass spectrometry for doping control.

Brooker L, Parr MK, Cawley A, Flenker U, Howe C, Kazlauskas R, Schänzer W, George A.

Drug Test Anal. 2009 Nov;1(11-12):587-95. doi: 10.1002/dta.108.

PMID:
20355175
45.

Terbutaline sulfoconjugate: characterization and urinary excretion monitored by LC/ESI-MS/MS.

Orlovius AK, Guddat S, Parr MK, Kohler M, Gütschow M, Thevis M, Schänzer W.

Drug Test Anal. 2009 Nov;1(11-12):568-75. doi: 10.1002/dta.84.

PMID:
20355173
46.

Combination of liquid-chromatography tandem mass spectrometry in different scan modes with human and chimeric mouse urine for the study of steroid metabolism.

Pozo OJ, Lootens L, Van Eenoo P, Deventer K, Meuleman P, Leroux-Roels G, Parr MK, Schänzer W, Delbeke FT.

Drug Test Anal. 2009 Nov;1(11-12):554-67. doi: 10.1002/dta.56.

PMID:
20355172
47.

Sports-related issues and biochemistry of natural and synthetic anabolic substances.

Parr MK, Flenker U, Schänzer W.

Endocrinol Metab Clin North Am. 2010 Mar;39(1):45-57, viii. doi: 10.1016/j.ecl.2009.11.004.

PMID:
20122449
48.

Detection of the misuse of steroids in doping control.

Parr MK, Schänzer W.

J Steroid Biochem Mol Biol. 2010 Aug;121(3-5):528-37. doi: 10.1016/j.jsbmb.2009.12.008. Epub 2009 Dec 28. Review.

PMID:
20036329
49.

CYP21-catalyzed production of the long-term urinary metandienone metabolite 17beta-hydroxymethyl-17 alpha-methyl-18-norandrosta-1,4,13-trien-3-one: a contribution to the fight against doping.

Zöllner A, Parr MK, Drăgan CA, Dräs S, Schlörer N, Peters FT, Maurer HH, Schänzer W, Bureik M.

Biol Chem. 2010 Jan;391(1):119-27. doi: 10.1515/BC.2010.002.

PMID:
19919183
50.

Detection and characterization of a new metabolite of 17alpha-methyltestosterone.

Pozo OJ, Van Eenoo P, Deventer K, Lootens L, Van Thuyne W, Parr MK, Schänzer W, Sancho JV, Hernández F, Meuleman P, Leroux-Roels G, Delbeke FT.

Drug Metab Dispos. 2009 Nov;37(11):2153-62. doi: 10.1124/dmd.109.028373. Epub 2009 Aug 24.

PMID:
19704028

Supplemental Content

Support Center